1	Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship
2	"Diamond Princess" in Japan
3	
4	Sakiko Tabata, M.D. ^{1†} , Kazuo Imai, M.D. ^{1,2*†} , Shuichi Kawano, M.D. ^{1,4} , Mayu Ikeda, M.D. ¹ ,
5	Tatsuya Kodama, M.D. ¹ , Kazuyasu Miyoshi, M.D. ¹ , Hirofumi Obinata, M.D. ^{1,3} , Satoshi Mimura,
6	M.D. ¹ , Tsutomu Kodera, M.D. ¹ , Manabu Kitagaki, M.D. ¹ , Michiya Sato, M.D. ¹ , Satoshi Suzuki,
7	M.D. ¹ , Toshimitsu Ito, M.D. ¹ , Yasuhide Uwabe, M.D. ¹ , Kaku Tamura, M.D. ¹
8	
9	
10	1. Self-Defense Forces Central Hospital, 24-2-1, Ikejiri, Setagaya-ku, Tokyo, Japan
11	2. Department of Infectious Disease and Infection Control, Saitama medical university, 38 Moro,
12	Hongo, Iruma-gun, Saitama, Japan
13	3. Department of Emergency and Critical Care Medicine, Nippon Medical School, 1-1-5, Sendagi,
14	Bunkyo-ku, Tokyo, Japan
15	4. Japan Ground Self-Defense Force Medical Service School, 24-2-1, Ikejiri, Setagaya-ku, Tokyo,
16	Japan
17	
18	* Corresponding author
19	[†] Both authors contributed equally
20	
21	
22	
23	
24	
25	
20 97	
21 90	
20 20	
29	
31	Corresponding author
32	Kazuo Imai M D
33	
34	Self-Defense Forces Central Hospital, 24-2-1, Ikeijri, Setagava-ku, Tokvo, Japan
35	Department of Infectious Disease and Infection Control. Saitama medical university, 38 Moro.
36	Hongo, Iruma-gun, Saitama, Japan
37	Mail; k_imai@saitama-med.ac.jp
38	Tel; 03-3411-0151 or 049-276-111

39 Abstract

40

41 Background

- 42 The ongoing outbreak of 2019 novel coronavirus disease (COVID-19) is a global threat. Clarifying
- 43 its clinical features such as risk factors for disease progression is a pressing issue. We analyzed the
- 44 difference between non-severe and severe cases with COVID-19 as a result of the mass infection on
- 45 a cruise ship "Diamond Princess" in Japan.

46 Methods

- 47 In this retrospective, single-center study, total 104 cases of laboratory-confirmed COVID-19 were
- 48 enrolled from the mass infection on the cruise ship from 11th to 25th Feb, 2020, at Self-Defense
- 49 Forces Central Hospital in Japan. Clinical records, laboratory data, and radiological findings were
- ⁵⁰ collected and analyzed. Clinical outcomes were followed up until 26th Feb, 2020.

51 Findings

- 52 Of the 104 patients, 47 were male. The median age was 68 years. During the observation period,
- ⁵³ eight patients deteriorated into the severe cases. Finally, 76 and 28 patients were classified as
- ⁵⁴ non-severe (asymptomatic, mild), and severe cases, respectively. Chest CT abnormalities were found
- in 43 in non-severe cases and 23 in severe cases. The prevalence of consolidation on chest CT scan
- ⁵⁶ and lymphopenia on the admission day was significantly higher in severe cases and in the eight cases
- 57 which worsened into severe disease during the observation period.

58 Interpretation

- ⁵⁹ The high proportion of non-severe cases corrects the assessment of the trend of the outbreak.
- 60 Consolidation on chest CT scan and lymphopenia were possible risk factors for deterioration of
- 61 COVID-19 and contribute to the clinical management.
- 62

63 Funding

- 64 Not applicable.
- 65

66 Research in context

67

68 Evidence before this study

- ⁶⁹ We looked into PubMed database for articles published in English up to 1st, Mar, 2020, using the
- ⁷⁰ keywords "novel coronavirus", "2019 novel coronavirus", "2019-nCoV", "Severe acute respiratory
- syndrome coronavirus 2", "SARS-CoV2", "COVID-19", "mass infection", "herd infection", "cruise
- ship", "Diamond Princess", "asymptomatic" and "subclinical". There were no published clinical
- ⁷³ studies of featuring COVID-19 as a result of mass infection of cruise ship. We found a published
- researches entitled "Characteristics of COVID-19 infection in Beijing.", and "Radiological findings
- from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study" comparing
- patients with COVID-19 between asymptomatic, mild, and severe cases. However, above researches

did not describe the marker of deterioration, or the risk factors for disease progression.

78 Added value of this study

- 79 We presented a high proportion of asymptomatic and mild cases in patients infected with severe
- acute respiratory syndrome coronavirus 2 (SARS-CoV2). On the admission day, the prevalence of
- consolidation detected by CT scan and lymphopenia were significant higher in severe cases and in
- cases which deteriorated into sever cases during the observation period. Consolidation on CT scan
- and lymphopenia reflect the disease progression. This report contributes to the improvement of the
- 84 epidemiological and clinical management of COVID-19.

85 Implications of all the available evidence

- ⁸⁶ There is a high prevalence of non-severe cases in patients infected with COVID-19 as a result of the
- 87 mass infection on a cruise ship. The prevalence of asymptomatic and mild cases of COVID-19
- contributes to the further assessment on the trend of outbreak. Consolidation detected by CT scan
- and lymphopenia are useful for the markers of disease progression.
- 90 91

92 Introduction

93

⁹⁴ The 2019 novel coronavirus disease (COVID-19) is caused by a novel coronavirus – severe acute

respiratory syndrome coronavirus 2 (SARS-CoV2). The first case was reported in Wuhan, China, in

96 December 2019, ¹ and the ongoing outbreak has been declared by the World Health Organization as a

97 Public Health Emergency of International Concern. Since the specific treatment for COVID-19 is

⁹⁸ unknown, detection of the patients who are at high risk of severe illness is necessary in order to

99 prepare sufficient supportive therapy. Also, explosive increase in patients caused a collapse of health

100 care system. Therefore triage of the patients and transportation to the proper facilities are required.

101 The knowledge of the clinical characteristics of the disease and pathogenicity of the virus is

- 102 increasingly accumulated. However, detail of the clinical characteristics is still unknown and most of
- 103 the articles previously printed are mainly focused on the severe cases of COVID-19. ²⁻⁵ In Japan, a
- 104 large number of infection among passengers and crew members of the cruise ship "Diamond
- ¹⁰⁵ Princess" occurred in Feb, 2020. By 1st March, 2020, over 700 people were laboratory-confirmed

106 with SARS-CoV2 infection. All symptomatic and asymptomatic cases were referred to the medical

107 institutions designated for infectious diseases in accordance with Infectious Diseases Control Law of

108 Japan. Approximately 15% of the laboratory-confirmed cases were admitted to Self-Defense Forces

- 109 Central Hospital in Japan.
- 110 The prevalence of asymptomatic and mild cases of COVID-19 contributes to the assessment of
- epidemic trend 6 . In the clinical settings, identifying the patients who are at risk of deterioration is
- essential. For these reasons, understanding of the differences between non-severe (asymptomatic and
- 113 mild) cases and severe cases is required.
- 114 Therefore, we retrospectively collected and analyzed detailed clinical findings in hospitalized cases

- 115 with COVID-19 of the cruise ship outbreak, including asymptomatic/mild and severe symptomatic
- 116 cases, at the Self-Defense Forces Central Hospital in Japan.
- 117
- 118 Methods
- 119

120 Study design and patients

We conducted a retrospective review on the medical records of 104 laboratory-confirmed patients 121 122 with COVID-19 who were referred to the Self-Defense Forces Central Hospital in Japan, since 11th 123to 25nd Feb 2020. In the cruise ship, all patients were examined under quantitative reverse 124 transcription polymerase chain reaction (qRT-PCR) or nested polymerase chain reaction (PCR) for 125SARS-CoV2 in the pharyngeal swab or sputum according to the recommendation by the National Institute of Infectious Disease at the public health institute.⁷ This study was reviewed and approved 126 by the Japan Self-Defense Forces Central Hospital (approval number 01-011). Both written and oral 127 128 informed consent was obtained from each enrolled patient.

129 Data collection

- 130 We retrospectively collected patient information from the electronic medical records of our hospital,
- including clinical records, laboratory findings, and chest CT scans. All information were collected
- and reviewed by two study investigators (ST and KI),

133 **Definitions**

- 134 The geographical regions were classified according to the standard country or area codes for
- 135 statistical use (M49) by the United Nations Statistics Division. Asymptomatic cases were defined as
- patients with no history of clinical signs and symptoms. Severe symptomatic cases were defined as
- 137 patients showing clinical symptoms of pneumonia (dyspnea, tachypnea, saturation of percutaneous
- ¹³⁸ oxygen (SpO2) <93%, and patients' need for oxygen therapy). ⁸ Other symptomatic cases were
- 139 classified as mild cases.

140 Statistical analysis

- 141 Continuous variables were expressed as mean standard deviation (SD) or median interquartile range
- 142 [IQR], and compared with under the T-test or Wilcoxon rank-sum test for parametric or
- 143 non-parametric data, respectively; categorical variables were expressed as number (%) and compared
- 144 by χ^2 test or Fisher's exact test. Multivariable logistic regression analysis was used for multivariate
- 145 analysis. The final multivariable logistic regression models were adjusted for age, sex, smoking, and
- any underlying disease. A two-sided *p*-value of less than 0.05 was considered statistically significant.
- 147 All statistical analyses were calculated using Stata13.
- 148Role of the funding source
- 149 There was no funding source for this study.
- 150
- 151 Result
- 152

153 During the observation period, total 107 laboratory-confirmed patients with COVID-19 from the

- 154 cruise ship were hospitalized at the Self-Defense Forces Central Hospital in Japan. Three patients
- were excluded from this study because of their withdrawal to join this study. Therefore, the
- remaining 104 patients were analyzed. Clinical history, physical examination and chest CT scan were
- 157 evaluated on the admission day, and blood tests were conducted within two days. The characteristics
- of the 104 patients are presented in Table 1. The age range was 25–93 years (median, 68 years; IQR,
- 159 46.75–75), and 47 patients (45.2%) were male. The most common nationality of patients was Eastern
- Asia, which included Japan and China. The observation period is from three to fifteen days (median,
- 161 10; IQR, 7–10 day). Fifty two patients (50.0 %) had comorbidities.
- 162 The clinical findings and severity of the patients before and after admission are shown on Table 2. Of
- the 104 patients, the most common clinical signs and symptoms presented before the admission were
- 164 fever (28.8%) and cough (27.9%). On the admission day, 43 patients (41.3%) didn't show any
- symptoms; therefore, these patients were classified as asymptomatic. Forty-one patients (39.4%)
- were classified as mild cases, and 20 patients (19.2%) were severe cases. During the observation
- 167 period, 80 new clinical signs and symptoms arose. Seven asymptomatic cases were reclassified as
- 168 mild cases. Three asymptomatic cases and five mild cases required oxygen therapy because of the
- pneumonia of COVID-19; thus, they were reclassified as severe cases. The confirmed classification
- of severity at the end of the observation is; 33 patients (31.7%) as asymptomatic, 43 patients (41.3%)
- as mild, and 28 patients (26.9 %) as severe. Describing about the eight patients who deteriorated and
- reclassified as severe cases, the age range was 42–87 years (median, 70 years; IQR, 70–77), and five
- patients (62.5%) were male. The period of deterioration from onset was 1-5 days (median, 4 days;
- 174 IQR, 2.5-5). Also, of all the patients, 14 patients (13.5%) needed oxygen therapy, and a patient
- required mechanical ventilation. None of the patients died during the observation period.
- 176
- 177 The differences in clinical, laboratory, and radiographic abnormality on the admission day between
- 178 non-severe cases and severe cases were analyzed. There were no significant differences observed in
- the distribution of age, sex, and comorbid condition between two groups (Table 3). Of the 76
- 180 non-severe patients, 43 patients (56.6%) manifested the abnormal findings on CT scan with various
- 181 patterns. (Figure 1). In univariate analyses, the prevalence of CT abnormality detected on the
- admission day was significantly higher in the severe cases than in non-severe cases (85.2% vs
- 183 56.6%; p = 0.03; OR, 3.53; 95% CI; 1.21-10.27). Significant differences in the prevalence of the CT
- 184 pattern were found between severe and non-severe cases as follows: bilateral lung findings (57.1%
- 185 vs 28.9%; OR, 3.27; 95% CI; 1.33–8.06; p = 0.01), multifocal ground-glass opacity (GGO) (63.0%)
- 186 vs 34.2%; OR, 2.97; 95% CI; 1.21–7.26; p = 0.02), and consolidation (48.1% vs 19.7%; OR, 3.52;
- 187 95% CI; 1.38–8.96; p = 0.01). With regard to blood tests, the elevation of aspartate transaminase
- 188 (AST) \geq 38 IU/dL (32.1% vs 11.8%; OR, 3.52; 95% CI; 1.22-10.12; p = 0.01) and depletion of
- 189 lymphocyte count <1,200 (/ μ L) (lymphopenia) (57.1% vs 25.0%; OR, 4.00; 95% CI; 1.61-9.95; $p < 10^{-10}$
- 190 0.01) in severe cases was significantly higher than in non-severe cases. Subsequently, the patients

- 191 who worsened to severe cases during the observation period (n=8) were compared with the patients
- in non-severe cases (n=76). In the patients who deteriorated, eight patients (100.0%) presented the
- radiographical abnormality on CT in prior to the typical pneumonia symptoms (Figure 2).
- 194 Consolidation on chest CT scan and lymphopenia were found in six (75.0%) and five patients
- 195 (62.5 %), respectively. In univariate analyses, the prevalence of consolidation (75.0% vs 19.7%; OR,
- 196 12.20; 95% CI; 2.23–66.59; p = 0.04) and lymphopenia (62.5% vs 25.0%; OR, 5.00; 95% CI;
- 197 1.10–22.92; p = 0.04) were found to be significant higher in the patients who worsened to severe
- 198 cases.
- 199 In multivariate analysis, the prevalence of consolidation detected by chest CT scan (adjusted OR:
- 200 3.24; 95% CI; 1.04-10.40; *p* = 0.04), and lymphopenia (adjusted OR, 4.30; 95% CI; 1.50-13.75; *p* <
- 201 0.01) were found to be significant higher in severe cases.
- 202
- 203

204 Discussion

205

In the outbreak of COVID-19 on the cruise ship "Diamond Princess," members of the cruise ship

were tested by PCR for SARS-CoV2 and all laboratory-confirmed cases were referred to the

hospitals. This situation is worthy to note because we observed the clinical course of even

- asymptomatic or mild symptomatic patients, which have not been investigated in the reports
- 210 previously published. ²⁻⁵

The possible risk factors for deterioration of COVID-19 have been unclear, because patients do not

visit hospitals if they are asymptomatic or only mild symptomatic. Based on the previous findings of

213 COVID-19 in China, old age, male sex, and presence of comorbidities may be risk factors for disease

²¹⁴ progression and poor prognosis.¹ In this study, the prevalence of consolidation detected by chest CT

scan and lymphopenia were significantly higher in severe cases and in the cases that worsened to

- severe condition during the observation period than in non-severe cases (p < 0.05). Therefore,
- consolidation and lymphopenia are considered as possible risk factors for disease progression of
- 218 COVID-19. Pan F, et al. and Shi H, et al. reported that the pattern of abnormal lung findings was
- varied from GGO into consolidation during the time course of COVID-19⁹, and the appearance of

220 consolidation became more frequent in patients within 1-3 weeks after symptom onset. ¹⁰ Previous

reports showed 55% of patients with COVID-19 developed dyspnea a median of 8 days (IQR,

- 222 5.0–13.0) after symptom onset, ¹ thus, the timing of appearance of consolidation on CT scan is
- associated with the timing of deterioration of the disease. Generally, consolidation is easily
- detectable in chest X-ray. It may be useful for evaluation for risk of the disease progression in the
- patients with COVID-19 in the setting with limited resources,
- With regard to blood tests, lymphopenia is a common feature in symptomatic COVID-19^{11,12}, and
- this can be caused by either direct effect of the SARS-CoV2 or cytokines. Lymphopenia was also
- frequently found in SARS¹³, and was considered as a marker of disease activity. ¹⁴ Our findings

suggest that lymphopenia may also reflect the disease progression and lead a new insight into the
 phenotype and pathogenicity of SARS-CoV2.

- 231 CT scan showed a high prevalence of abnormality in lungs in non-severe cases (56.6 %) and severe
- cases (85.1 %), and that findings are also seen even in asymptomatic cases. Shi H, et al. also
- 233 mentioned these asymptomatic abnormal lung findings in their report focusing on the radiological
- ²³⁴ findings on CT scan of COVID-19 cases. ¹⁰ This interesting clinical feature of the SARS-CoV2
- 235 infection has not been reported in the SARS-CoV or Middle East respiratory syndrome coronavirus
- 236 (MERS-CoV). All of the eight patients, who reclassified as severe cases from non-severe case during
- the observation period, presented CT abnormality in advance of the appearance of typical pneumonia
- symptoms. Moreover, less than half of the patients had no obvious symptoms such as fever and
- cough. These facts warn us that COVID-19 pneumonia progresses "silently" without any remarkable
- symptoms. Assessment with the blood test and chest CT scan might lead to a successful devotion of
- 241 medical resources to the patients who have the risk of disease progression in the setting and mass
- infection as well as in the normal clinical settings. On the other hand, majority of asymptomatic
- cases with radiological abnormality on CT scan did not develop the severe pneumonia. The
- ²⁴⁴ difference of clinical outcomes may associate with their background, and genetic and pathogenic
- ²⁴⁵ diversity of SARS-CoV2. Understanding of its relevance to the duration of virus shedding or to the
- incidence rate of secondary bacterial pneumonia is important for improvement of clinical
- ²⁴⁷ management. Further study is required to clarify this clinical impact in the asymptomatic and mild
- patients with COVID-19.
- It is important to determine the proportion of asymptomatic and mild cases to assess not only the risk
- 250 of subsequent outbreaks but also the future trends. ⁶ Generally, asymptomatic and mild infections
- 251 contribute to herd immunity and its dampening effect on epidemic spread. ^{6,15} However, the
- prevalence of asymptomatic and mild cases of COVID-19 has not been elucidated because detection
- of the asymptomatic case by RT-PCR is not realistic, except for the limited situation like a mass
- infection. In this study, we showed that 73.0 % of the patients in the mass infection on a cruise ship
- were asymptomatic and mild cases, and the proportion was higher than previously reported 6,11,16 .
- However, the sensitivity of RT-PCR is considered insufficient 17 , and the accurate prevalence is still
- ²⁵⁷ underestimated. The serological screening by using specific antibody of COVID-19 is expected to
- 258 confirm our result. Many countries and institutions are using contact tracing in the surveillance of
- 259 COVID-19. However, it is suggested that the large number of asymptomatic and mild patients may
- 260 have been overlooked in the past.
- Viral RNA was frequently detected through throat swabs or sputum even in asymptomatic and mild
- symptomatic patients. In Germany and China, the transmission from an asymptomatic patient to
- another person has been reported. ¹⁸⁻²⁰ Zou L, et al. showed that viral RNA was detected in the upper
- respiratory specimen in asymptomatic patients over 11 days, and the viral load of an asymptomatic
- ²⁶⁵ patient was equivalent to that of symptomatic cases. ²¹ Also, the fact that we found CT abnormality
- even in the asymptomatic patients also suggest that they may have a certain amount of viral load.

267	Previous findings along with our results may support the evidence that asymptomatic patients also
268	shed the SARS-CoV2 from the upper respiratory tract. Also, during the mass infection on the cruise
269	ship, there was a possibility that both asymptomatic and symptomatic patients spread the
270	SARS-CoV2. Further study is desired to clarify the transmission from an asymptomatic patient to
271	another person.
272	The limitations of this study were the selection bias and small number of patients. We enrolled the
273	ideal homogeneous clusters of relatively healthy person who can get aboard a cruise ship for a long
274	term. However, our patient population and was not completely representative of patients in the
275	normal clinical settings. In addition, there were only a few patients who deteriorated into severe
276	cases from non-severe case during the observation period in this study. Therefore, further multicenter,
277	multi-national cohort study is desired to determine the prediction marker of diseases progression.
278	
279	
280	Conclusion
281	
282	Our study highlighted the high prevalence of asymptomatic and mild cases of COVID-19 as a result
283	of mass infection on a cruise ship. Consolidation on CT scan and lymphopenia may reflect the risk of
284	disease progression. Our findings contribute to estimate the future trend of outbreaks, better
285	understanding of clinical course and improvement of the management of COVID-19. Further cohort
286	study is needed to determine the prediction marker of diseases activity.
287	
288	Competing interest
289	
290	The authors declare that they have no conflicts of interests.
291	
292	Funding
293	
294	This research did not receive any specific grant from funding agencies in the public, commercial, or
295	nonprofit sectors.
296	
297	Authors' contributions
298	
299	TI and KT, study conception and design; ST and KI, collecting data and performed the data analysis;
300	ST, KI, MI, and KM manuscript drafting, and editing; TaK, HO, SK, TsK, MK and SM, manuscript
301	revision; MS, SS and UY, study supervision. All authors read and approved the final manuscript.
302	
303	Acknowledgments
304	

305	We thank everyone involved in the COVID-19 management and treatment team from the					
306	Self-Defense Forces Central Hospital in Japan and members who were assembled from other					
307	institutes of Japan Self-Defense Forces. Particularly, we thank Dr. Koji Kameda, Dr. Takayuki					
308	Yamamoto, Dr. Daishi Higashiyama, Dr. Yoshitaka Imoto, Dr. Masataka Miyama, Dr. Tsukasa					
309	Mizuno, Dr. Kento Kato, Dr. Masaru Honda, Dr. Shoji Takeda, and Dr. Masumi Ogawa, Dr. Shingo					
310	Tanaka, Dr. Hisashi Sasaki, Dr. Mitsuki Yamaga, Dr. Shinichiro Ota and Dr. Hiroaki Taniguchi for					
311	supporting the data collection, and Dr. Akira Fujikawa and Dr. Shohei Inui for the interpretation of					
312	chest CT scan. We also thank Mr. Shingo Tamaki (School of Tropical Medicine and Global Health,					
313	Nagasaki University, Japan) for the supporting statistical analysis, and Colonel. Kazuhiro Nakaya					
314	(Medical Department, Ground Staff Office, Ministry of Defense) for the scientific advice.					
315						
316						
317	References					
318						
319	1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel					
320	coronavirus in Wuhan, China. The Lancet 2020; 395: 497-506.					
321	2. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected by					
322	SARS-CoV-2 in Wuhan, China. Allergy 2020.					
323	3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of					
324	2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020; 395:					
325	507-13.					
326	4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019					
327	Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020.					
328	5. Li K, Wu J, Wu F, et al. The Clinical and Chest CT Features Associated with Severe and					
329	Critical COVID-19 Pneumonia. Investigative Radiology 2020.					
330	6. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus					
331	Emerging in China - Key Questions for Impact Assessment. The New England Journal of Medicine					
332	2020; 382 : 692-4.					
333	7. Nao N, Shirato K, Katano H, et al. Detection of second case of 2019-nCoV infection in					
334	Japan. National Institute of Infectious Diseases.					
335	.https://www.niid.go.jp/niid/images/vir3/nCoV/method-niid-20200123-2_erratum.pdf [Latest					
336	accessed 1/Mar/2020]					
337	8. Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for					
338	2019 novel coronavirus disease in fever clinics. The Lancet Respiratory Medicine.					
339	9. Pan F, Ye T, Sun P, et al. Time Course of Lung Changes On Chest CT During Recovery					
340	From 2019 Novel Coronavirus (COVID-19) Pneumonia. Radiology 2020: 200370.					
341	10. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19					
342	pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious Diseases.					

- Guan W-j, Ni Z-y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in
 China. *New England Journal of Medicine* 2020.
- Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission
 potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.
 The Lancet.
- Wong RS, Wu A, To KF, et al. Haematological manifestations in patients with severe acute
 respiratory syndrome: retrospective analysis. *BMJ* 2003; **326**: 1358-62.
- Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of
 144 patients with SARS in the greater Toronto area. *JAMA* 2003; 289: 2801-9.
- Bellan SE, Pulliam JRC, Dushoff J, Meyers LA. Ebola control: effect of asymptomatic
 infection and acquired immunity. *The Lancet* 2014; **384**: 1499-500.
- 16. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus
 (2019-nCoV) in Wuhan, China. *Journal of Medical Virology* 2020; **92**: 441-7.
- Huang P, Liu T, Huang L, et al. Use of Chest CT in Combination with Negative RT-PCR
 Assay for the 2019 Novel Coronavirus but High Clinical Suspicion. *Radiology* 2020: 200330.
- 18. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an
 Asymptomatic Contact in Germany. *The New England Journal of Medicine* 2020.
- Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19.
 JAMA 2020.
- Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the
 2019 novel coronavirus indicating potential person-to-person transmission during the incubation
 period. *The Journal of Infectious Diseases* 2020.
- Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens
 of Infected Patients. *The New England Journal of Medicine* 2020.
- 367
- 368

369 Figure Legends

370

Figure 1. The CT pattern of abnormal lung findings among asymptomatic patients with COVID-19.

A patient 73 years old, female. The patchy non-segmental ground grass opacity (GGO) adjacent to

the parietal pleura in the right upper lobe (A and B), and in both lower lobes (C and D). A patient 70

years old, female. The GGO with interlobular septal thickening (crazy-paving appearance) adjacent

to the parietal pleura in the both lower lobes (E). A patient 76 years old, male. CT scan showed the

- 376 GGO with consolidation, bronchial wall thickening, and bronchiectasis in the left lower lobe (F).
- 377

Figure 2. The progress of CT findings in a patient with COVID-19. A male patient 75 years old was asymptomatic on the admission day. On the fourth day of admission, he showed tachypnea and hypoxemia, and treated oxygen therapy. On the admission day, Chest CT scan showed multifocal

- 381 GGO adjacent to the parietal pleura in multiple lobes with emphysematous changes (A, B and C). On
- the tenth day of admission, a follow-up chest CT scan showed an increase of extent of GGO with
- 383 crazy-paving appearance (D, E and F).
- 384

Total number of patients $(n = 104)$					
Characteristics					
Age	68 [46.75–75]				
Sex (male)	47 (45.2 %)				
Observation period (days)	10 [7-10]				
The period onset to admission (days)	5 [2 - 7]				
Nationality					
Eastern Asia	55 (52.9%)				
Southeast Asia	21 (20.2%)				
Europe	4 (3.8%)				
Northern America	14 (13.5%)				
Oceania	4 (3.8%)				
Others	6 (5.8%)				
Smoking					
Yes	18 (17.3%)				
Comorbid condition					
Total	52 (50.0%)				
Cardiovascular	31 (29.8%)				
Endocrine	9 (8.7%)				
Diabetes mellitus	7 (6.7%)				
Respiratory	7 (6.7%)				
Carcinoma	4 (3.8%)				

Table1: The baseline characteristics of patients with COVID-19 from the cruise ship

386 Data are n (%) or median (IQR), unless otherwise specified.

	Number (%) n = 104			
	Started before the admission	End of the observation period		
Signs and symptoms				
Fever	30 (28.8%)	36 (34.6%)		
Cough	29 (27.9%)	43 (41.3%)		
Malaise	12 (11.5%)	22 (21.2%)		
Headache	10 (9.6%)	18 (17.3%)		
Sore throat	11 (10.6%)	11 (10.6%)		
Runny nose	16 (15.4%)	25 (24.0%)		
Diarrhea	8 (7.7%)	10 (9.6%)		
Dyspnea	7 (6.7%)	19 (18.3%)		
Tachypnea	16 (15.4%)	24 (23.1%)		
SpO2 < 93 %	3 (2.9%)	14 (13.5%)		
Treatment				
Oxygen therapy	3 (2.9%)	14 (13.5%)		
Mechanical ventilation	-	1 (1.0%)		
Severity				
Asymptomatic	43 (41.3%)	33 (31.7%)		
Mild	41 (39.4%)	43 (41.3%)		
Severe	20 (19.2 %)	28 (26.9%)		

388 Table 2. Clinical findings and severity of patients with COVID-19

389 Data are n (%)

			Univariate		Multivariate	
	Non-severe n = 76	Severe n = 28	p-value	OR	p-value	Adjusted OR
Characteristics						
Age	66.5 [44.75-74]	72.5 [55.25-76.5]	0.08		0.62	
Sex (male)	32 (42.1%)	15 (53.6%)	0.37		0.28	
Smoking						
Yes	11 (14.5%)	7 (25.0%)	0.24		0.08	
Underlying disease						
Total	34 (44.7%)	18 (64.3%)	0.12		0.18	
Radiographically findings or	n the day of adr	nission				
Abnormal lung finding	43 (56.6%)	23 (82.1%)	0.02*	3.53 (1.21-10.27)		
Bilateral lung findings	22 (28.9%)	16 (57.1%)	0.01*	3.27 (1.33-8.03)		
Multifocal GGO	26 (34.2%)	17 (60.7 %)	0.02*	2.97 (1.21-7.26)		
Consolidation	15 (19.7%)	13 (46.4 %)	0.01*	3.52 (1.38-8.96)	0.04*	3.24 (1.04 - 10.40)
Laboratory findings on the d	lay of admission	n				
AST > 38 (IU/L)	9 (11.8%)	9 (32.1%)	0.02*	3.52 (1.22-10.12)	0.07	
ALT > 45 (IU/L)	10 (13.2%)	7 (25.0%)	0.22			
LDH > 230 (IU/L)	17 (22.4%)	10 (35.7%)	0.21			
CRP > 1.0 (mg/dL)	34 (44.7 %)	19 (67.9%)	0.07			
White blood cell count < 4000 (/µL)	13 (17.1%)	6 (21.4%)	0.58			
Platelet count $< 20 \; (\times 10^4 / \mu L)$	6 (7.9%)	2 (7.1%)	1.00			
Lymphocyte count <1200 (/µL)	19 (25.0%)	16 (57.1%)	< 0.01*	4.00 (1.61-9.95)	< 0.01*	4.30 (1.50-13.75)

Table 3. The differences in clinical characteristics between non-severe cases and severe cases on the admission day

393 Data are n (%), or median [IQR], unless otherwise specified.

394 OR, odds ratio; 95% CI, 95% confidence interval; GGO, ground-glass opacity; AST, aspartate

aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CRP, C reactive

396 protein.

- 397 Asterisk indicated the statistical significance.
- 398



